Distinguished in NUT Carcinoma

Dr. Benjamin G. Vincent

Hematology Oncology | Hematology | Oncology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in NUT Carcinoma
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical Research

Overview

Benjamin Vincent is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Vincent is rated as a Distinguished provider by MediFind in the treatment of NUT Carcinoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Triple-Negative Breast Cancer, NUT Carcinoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vincent is currently accepting new patients.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of NUT Carcinoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Cyclophosphamide
Study Phase: Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
View 4 Less Clinical Trials

125 Total Publications

PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity.
PARP7 Suppresses Radiation-induced Necroptosis and Abscopal Immunity.
Journal: Research square
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vincent's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile